Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Polycystic Ovary Syndrome 13Insulin Resistance 3Hyperandrogenism 3Metabolic Syndrome 2Solid Tumors 1Primary Dysautonomias 1Overweight 1Motor Activity 1Menstruation Disturbances 1Infertility 1Hirsutism 1Endometrial Neoplasms 1Depression 1Breast Neoplasms 1Bipolar Disorder 1Anxiety Disorders 1Advanced Malignancies 1

Interventions

tanespimycin 2pembrolizumab 2parsaclisib 2cemiplimab 2Midazolam 2MLN 8237 2Injections 2Capecitabine 2zanidatamab 1tislelizumab 1spartalizumab 1sitravatinib 1repaglinide 1pemigatinib 1pamiparib 1liposomal doxorubicin 1lenvatinib 1epothilone B 1drospirenone 1cabiralizumab 1Temozolomide 1Pemetrexed 1Paclitaxel 1Nivolumab 1N-alpha-(2,4,6-triisopropyl-phenylsulfonyl)-3-amidino-(L)-phenyl-alanine-4-ethoxycarbonyl-piperazide hydrochloride 1MLN8054 1Ipilimumab 1HMPL-013 1Gemcitabine 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Advanced Malignancies × Ethinyl Estradiol × Clear all
NCT07340190 2026-04-02

A Drug-drug Interaction Study to Evaluate the Effects of Pelabresib on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Oral Contraceptive in Patients With Advanced Malignancies

Novartis

Phase 1 Not yet recruiting
24 enrolled

Advanced Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡